2021IM PIPELINES SESSION

OPEN DISCUSSION ON PIPELINES OF EXPERIMENTAL TREATMENTS FOR ASTHMA, ALLERGY/RHINITIS, COPD, MULTIMORBIDITY: PANEL DISCUSSION OF RD DIRECTORS OF THE MAIN RESPIRATORY PHARMA INDUSTRIES
Conductors Leonardo M. Fabbri, Pierluigi Paggiaro, Alberto Papi and Giovanni Passalacqua

Introduzione

 

Mark Parry-Billings
Head of Corporate Drug Development
Chiesi Farmaceutici

 

Carmen Stabile
Respiratory Medical Lead
GlaxoSmithKline Spa – Pharmaceuticals

 

Andrea Rizzi
Medical Director Respiratory & Allergy and Diabetes
Ilaria Barisone
Clinical Research Medical Advisor
Novartis Italia

 

Devis Moretti
Medical Lead Immunology
Sanofi Genzyme

 

Berta Juliá de Páramo
Regional Director Medical Affairs (EUCAN)
Respiratory, MSD

 

Najy Alsayed
Global Therapeutic Area Head – Infectious Diseases
Menarini Group

 

Rita De Santis
Head Biotechnology Research and Development
Alfasigma

 

Maria Belvisi
SVP Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D
AstraZeneca

 

Discussione

 

Posted in Firenze 2021.